Inclusion Criteria:

1. Patients must have histologically documented primary FIGO Stage III or IV or
recurrent endometrial carcinoma whose potential for cure by radiation therapy or
surgery alone or in combination is very poor. Pathologic documentation of the
recurrence is required.

2. Patients must have measurable disease as defined in section 8, under Criteria for
Response. Disease in an irradiated field as the only site of measurable disease is
acceptable only if there has been clear progression since completion of radiation
treatment.

3. Patients may have received an unlimited amount of prior therapy, including
platinum-based therapy, but such therapies must be discontinued at least 3 weeks
prior to entry on this study. At least two weeks must have elapsed from the
completion of radiotherapy and the start of therapy and six weeks must have elapsed
if the radiotherapy involved the whole pelvis or over 50% of the spine, provided the
acute effects of radiation treatment have resolved. Hormonal therapy may be
discontinued at any time prior to initiating the protocol.

4. Patients must have adequate organ function as follows: Platelets >/= 100,000/ul;
Granulocytes (ANC) >/= 1,500/ul; Creatinine limit of normal, and Bilirubin
5. Neuropathy (sensory and motor) should be less than or equal to CTCAE grade 1.

6. Patients must have a Zubrod Performance Status of 0, 1, or 2.

7. Patients must have signed an approved informed consent.

8. Patients must have recovered from effects of recent surgery or radiotherapy. They
should be free of significant infection.

Exclusion Criteria:

1. Patients previously treated with gemcitabine.

2. Patients with a concomitant malignancy, other than non-melanoma skin cancer.

3. Patients with papillary serous or clear cell carcinoma of the endometrium, or
patients with malignant mixed mullerian tumor of the uterus.

4. Patients with a prior malignancy who have been disease-free for less than 5 years.

5. Patients with concomitant medical illness such as serious uncontrolled infection,
uncontrolled angina or serious peripheral neuropathy which, in the opinion of the
treating physician, make the treatments prescribed on the study unreasonably
hazardous for the patient.

6. Patients with renal dysfunction, chronic or acute kidney disease, or renal failure
which, in the opinion of the treating physician, would make the treatments prescribed
on the study unreasonably hazardous for the patient.

7. Patients whose circumstances will not permit study completion or adequate follow-up.

8. Patients who have no measurable disease.

9. Patients with a life expectancy of less than 3 months.